Effect of bisphosphonates on bone giant cell tumor recurrence: a meta-analysis
Abstract Background We examined the impact of bisphosphonates as adjuvant therapy on the recurrence of giant cell bone tumors and the impact of various tumor stages and surgical techniques on this effect. Following a thorough examination of the literature up to January 2022, 10 studies including 601...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SpringerOpen
2022-09-01
|
| Series: | Beni-Suef University Journal of Basic and Applied Sciences |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s43088-022-00292-2 |
| _version_ | 1811211688255422464 |
|---|---|
| author | Marwa Mohsen Hasnaa Osama Mina Nicola Haitham Saeed Mohamed E. A. Abdelrahim |
| author_facet | Marwa Mohsen Hasnaa Osama Mina Nicola Haitham Saeed Mohamed E. A. Abdelrahim |
| author_sort | Marwa Mohsen |
| collection | DOAJ |
| description | Abstract Background We examined the impact of bisphosphonates as adjuvant therapy on the recurrence of giant cell bone tumors and the impact of various tumor stages and surgical techniques on this effect. Following a thorough examination of the literature up to January 2022, 10 studies including 601 adults with giant cell tumors of the bone were reported; 295 of these subjects received bisphosphonates as adjuvant therapy following surgery, and 306 served as the control group. To examine the possibility of lowering the recurrence of giant cell bone tumors, a comparison between bisphosphonates and a control group was made. In order to evaluate the impact of bisphosphonates as adjuvant therapy on the recurrence of the giant cell bone tumor, odds ratios (OR) with 95% confidence intervals (CIs) were determined. Additionally, the dichotomous technique with a random or fixed-effect model was used to examine the effects of various tumor stages and pertinent surgical procedures. Results Patients with giant cell tumors of the bone who received bisphosphonates as adjuvant therapy had significantly lower postoperative recurrence rates outcomes in all subjects with giant cell tumor of bone (OR 0.19; 95% CI 0.12–0.31, p = 0.001), patients with stage I–II giant cell tumors of the bone (OR 0.29; 95% CI 0.11–0.76, p = 0.01), patients with stage III giant cell tumors of the bone (OR 0.17; 95% CI 0.07–0.42, p < 0.001); and post-intralesional curettage (OR 0.18; 95% CI 0.06–0.49, p < 0.001) compared to control. Bisphosphonates were used in participants with giant cell tumors of the bone after broad excision, but there was no discernible difference between the two groups in terms of postoperative recurrence outcomes (OR 0.66; 95% CI 0.11–3.91, p = 0.65). Conclusions In patients with giant cell tumors of the bone after intralesional curettage, the use of bisphosphonates as adjuvant therapy may lower the incidence of postoperative recurrence outcomes, but no appreciable difference was identified after extensive resection. According to the observed relationship, using bisphosphonates is advised to lower the likelihood of postoperative recurrence that can happen in patients with giant cell tumors of the bone. |
| first_indexed | 2024-04-12T05:16:25Z |
| format | Article |
| id | doaj.art-d7ef404075354eeea913fab884510665 |
| institution | Directory Open Access Journal |
| issn | 2314-8543 |
| language | English |
| last_indexed | 2024-04-12T05:16:25Z |
| publishDate | 2022-09-01 |
| publisher | SpringerOpen |
| record_format | Article |
| series | Beni-Suef University Journal of Basic and Applied Sciences |
| spelling | doaj.art-d7ef404075354eeea913fab8845106652022-12-22T03:46:37ZengSpringerOpenBeni-Suef University Journal of Basic and Applied Sciences2314-85432022-09-011111810.1186/s43088-022-00292-2Effect of bisphosphonates on bone giant cell tumor recurrence: a meta-analysisMarwa Mohsen0Hasnaa Osama1Mina Nicola2Haitham Saeed3Mohamed E. A. Abdelrahim4Clinical Pharmacy Department, Faculty of Pharmacy, Beni-Suef UniversityClinical Pharmacy Department, Faculty of Pharmacy, Beni-Suef UniversityClinical Pharmacy Department, Faculty of Pharmacy, Beni-Suef UniversityClinical Pharmacy Department, Faculty of Pharmacy, Beni-Suef UniversityClinical Pharmacy Department, Faculty of Pharmacy, Beni-Suef UniversityAbstract Background We examined the impact of bisphosphonates as adjuvant therapy on the recurrence of giant cell bone tumors and the impact of various tumor stages and surgical techniques on this effect. Following a thorough examination of the literature up to January 2022, 10 studies including 601 adults with giant cell tumors of the bone were reported; 295 of these subjects received bisphosphonates as adjuvant therapy following surgery, and 306 served as the control group. To examine the possibility of lowering the recurrence of giant cell bone tumors, a comparison between bisphosphonates and a control group was made. In order to evaluate the impact of bisphosphonates as adjuvant therapy on the recurrence of the giant cell bone tumor, odds ratios (OR) with 95% confidence intervals (CIs) were determined. Additionally, the dichotomous technique with a random or fixed-effect model was used to examine the effects of various tumor stages and pertinent surgical procedures. Results Patients with giant cell tumors of the bone who received bisphosphonates as adjuvant therapy had significantly lower postoperative recurrence rates outcomes in all subjects with giant cell tumor of bone (OR 0.19; 95% CI 0.12–0.31, p = 0.001), patients with stage I–II giant cell tumors of the bone (OR 0.29; 95% CI 0.11–0.76, p = 0.01), patients with stage III giant cell tumors of the bone (OR 0.17; 95% CI 0.07–0.42, p < 0.001); and post-intralesional curettage (OR 0.18; 95% CI 0.06–0.49, p < 0.001) compared to control. Bisphosphonates were used in participants with giant cell tumors of the bone after broad excision, but there was no discernible difference between the two groups in terms of postoperative recurrence outcomes (OR 0.66; 95% CI 0.11–3.91, p = 0.65). Conclusions In patients with giant cell tumors of the bone after intralesional curettage, the use of bisphosphonates as adjuvant therapy may lower the incidence of postoperative recurrence outcomes, but no appreciable difference was identified after extensive resection. According to the observed relationship, using bisphosphonates is advised to lower the likelihood of postoperative recurrence that can happen in patients with giant cell tumors of the bone.https://doi.org/10.1186/s43088-022-00292-2Giant cell tumor of boneBisphosphonatesRecurrenceIntralesional curettageWide resection |
| spellingShingle | Marwa Mohsen Hasnaa Osama Mina Nicola Haitham Saeed Mohamed E. A. Abdelrahim Effect of bisphosphonates on bone giant cell tumor recurrence: a meta-analysis Beni-Suef University Journal of Basic and Applied Sciences Giant cell tumor of bone Bisphosphonates Recurrence Intralesional curettage Wide resection |
| title | Effect of bisphosphonates on bone giant cell tumor recurrence: a meta-analysis |
| title_full | Effect of bisphosphonates on bone giant cell tumor recurrence: a meta-analysis |
| title_fullStr | Effect of bisphosphonates on bone giant cell tumor recurrence: a meta-analysis |
| title_full_unstemmed | Effect of bisphosphonates on bone giant cell tumor recurrence: a meta-analysis |
| title_short | Effect of bisphosphonates on bone giant cell tumor recurrence: a meta-analysis |
| title_sort | effect of bisphosphonates on bone giant cell tumor recurrence a meta analysis |
| topic | Giant cell tumor of bone Bisphosphonates Recurrence Intralesional curettage Wide resection |
| url | https://doi.org/10.1186/s43088-022-00292-2 |
| work_keys_str_mv | AT marwamohsen effectofbisphosphonatesonbonegiantcelltumorrecurrenceametaanalysis AT hasnaaosama effectofbisphosphonatesonbonegiantcelltumorrecurrenceametaanalysis AT minanicola effectofbisphosphonatesonbonegiantcelltumorrecurrenceametaanalysis AT haithamsaeed effectofbisphosphonatesonbonegiantcelltumorrecurrenceametaanalysis AT mohamedeaabdelrahim effectofbisphosphonatesonbonegiantcelltumorrecurrenceametaanalysis |